MARC details
000 -LEADER |
fixed length control field |
02982nam a22003497a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
190314s20192019 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
2471-254X |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1002/hep4.1304 [doi] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
HEP41304 [pii] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
PMC6357828 [pmc] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
30766960 |
245 ## - TITLE STATEMENT |
Title |
Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. |
251 ## - Source |
Source |
Hepatology Communications. 3(2):220-226, 2019 Feb. |
252 ## - Abbreviated Source |
Abbreviated source |
Hepatol. commun.. 3(2):220-226, 2019 Feb. |
253 ## - Journal Name |
Journal name |
Hepatology communications |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2019 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2019 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Publication status |
epublish |
266 ## - Date added to catalog |
Date added to catalog |
2019-03-14 |
520 ## - SUMMARY, ETC. |
Abstract |
Nonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for de novo steatosis during chemotherapy for non-Hodgkin lymphoma (NHL). In this retrospective case-control study, adult patients with NHL were treated with rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine (R-CHOP) or R-CHOP + etoposide (EPOCH-R). Patients with liver disease or steatosis were excluded. Abdominal computed tomography was performed pretreatment and at 3- to 6-month intervals and reviewed for steatosis. Patients with de novo steatosis were matched 1:1 to controls by age, sex, and ethnicity. Of 251 treated patients (median follow-up 53 months), 25 (10%) developed de novo steatosis, with the vast majority (23 of 25; 92%) developing it after chemotherapy. Of those, 14 (61%) developed steatosis within the first 18 months posttreatment and 20 (87%) within 36 months. Cases had higher baseline body mass index (BMI; mean +/- SD, 29.0 +/- 6.5 versus 26.0 +/- 5.2 kg/m<sup>2</sup>; P = 0.014) and hyperlipidemia (12% versus 2%; P = 0.035). Although their weights did not change during chemotherapy, BMI in cases increased by 2.4 +/- 2 kg/m<sup>2</sup> (mean +/- SD) from end of treatment to steatosis compared to 0.68 +/- 1.4 in controls (P = 0.003). Etoposide-containing regimens were associated with a shorter time to steatosis (median 34 weeks versus 154 weeks; P < 0.001) despite similar baseline risk factors. Conclusion: The recovery period from NHL chemotherapy appears to be a "hot spot" for development of fatty liver, driven by early posttreatment weight gain, especially in subjects with baseline risk factors. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/General Internal Medicine |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Cho, Min Ho |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Hemmati, Mehdi |
790 ## - Authors |
All authors |
Alao H, Ben-Yakov G, Cho MH, Dunleavy K, Fryzek N, Haydek JP, Hemmati M, Jones EC, Rotman Y, Samala V, Shovlin M, Wilson W |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1002/hep4.1304">https://dx.doi.org/10.1002/hep4.1304</a> |
Public note |
https://dx.doi.org/10.1002/hep4.1304 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |